The rest of this story is for members
The rest is for members
The story continues: the full timeline, the transaction ranges, and the names the forms carry.
Premium comes through the Telegram channel. Already have a code? Sign in to activate it.
Premium
OTLK
Suspicious movements in Outlook Therapeutics stock
Stock purchases totaling millions of dollars by directors and interested parties in biopharma company OTLK raise questions about the timing of the purchases, just before a resubmission of an FDA approval application.
Other Stories
Super unusual activity in a small and dangerous company!
PremiumInsidersTENX12h ago2 min read
5 investment firms cut targets, and the executive bought anyway. Since then: 92.6% increase
PremiumInsidersNIQ13h ago2 min read
Unusual insider buying alert
PremiumInsidersINBX14h ago2 min read